AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Leishmaniasis vaccine protects susceptible mice from virulent challenge.
2004 MAY 5 - (NewsRx.com & NewsRx.net) -- Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response.
According to published research from the United States, "Long-term immunity to Leishmania may require the continued presence of parasites, but previous attempts to create attenuated parasites that persist without causing disease have had limited success. Since Leishmania major mutants that lack lipophosphoglycan and other secreted phosphoglycans, termed lpg2[superscript]-, persist indefinitely in infected mice without inducing any disease, we tested their ability to provide protection to virulent L. major challenge.
"In response to leishmanial antigen stimulation, cells from lpg2[superscript]--infected mice produced minimal levels of IL-4 and IL-10, as well as very low levels of IFN-gamma," reported Jude E. Uzonna and collaborators at the University of Pennsylvania and Washington University. "Nevertheless, when BALB/c mice infected with lpg2[superscript]- parasites were challenged with virulent L. major they were protected from disease. Thus, these ...
- Leishmaniasis vaccine enters trials.
- Newspaper article from: Pharma Marketletter January 20, 2003 700+ words
Corixa Corp and the Infectious Disease Research Institute, both based in the USA, have started clinical trials of a vaccine designed to treat and protect against various human forms of the parasitic infection leishmaniasis. The vaccine, Leish-111f, consists of three fused Leishmania protein
- Corixa and IDRI Initiate U.S. Phase I Trial of Leishmaniasis Vaccine.
- Press release article from: Business Wire January 13, 2003 700+ words
Business Editors & Health/Medical Writers BIOWIRE2K SEATTLEBUSINESS WIREJan. 13, 2003 Corixa Corporation (Nasdaq: CRXA), a developer of immunotherapeutics, and the Infectious Disease Research Institute (IDRI), today announced that they have initiated a Phase I clinical trial to test the safety
- Immunotherapeutic antigens encapsulated in liposomes characterized.(Brief...
- Newspaper article from: Vaccine Weekly January 22, 2003 700+ words
...N St. NW, Washington, DC 20036-2904, USA. The information in this article comes under the major subject areas of Leishmaniasis, Vaccine Development. This article was prepared by Vaccine Weekly editors from staff and other reports.
- Immunology of susceptibility and resistance to Leishmania major reviewed.
- Newspaper article from: Vaccine Weekly March 12, 2003 700+ words
...Crinan Street, London N1 9XW, UK. The information in this article comes under the major subject areas of Leishmaniasis, Vaccine Development, and Immunology. This article was prepared by Vaccine Weekly editors from staff and other reports.
- Leishmania mexicana cysteine protease, CPB2.8, induces potent Th2 responses.
- Newspaper article from: Vaccine Weekly April 2, 2003 700+ words
...Bethesda, MD 20814, USA. The information in this article comes under the major subject areas of Leishmaniasis, Vaccine Development, and Vaccine Efficacy. This article was prepared by Vaccine Weekly editors from staff and other reports.
- Vaccine composed of FML antigen and saponin protects against leishmaniasis.
- Newspaper article from: Vaccine Weekly February 12, 2003 700+ words
...against murine visceral leishmaniasis. Vaccine, 2002;21(1-2...the major subject areas of Leishmaniasis, Vaccine Development, Vaccine Adjuvant...article was prepared by Vaccine Weekly editors from staff and other...
- Immunity and immunosuppression in visceral leishmaniasis reviewed.
- Newspaper article from: Vaccine Weekly July 7, 2004 700+ words
...Immunology, Immunotherapy, Leishmaniasis Vaccine, Vaccine Development, Tropical...This article was prepared by Vaccine Weekly editors from staff and other reports. Copyright 2004, Vaccine Weekly via NewsRx.com & NewsRx...
- Leishmanial amastigote antigen induces natural killer-cell reactivity.
- Newspaper article from: Vaccine Weekly May 26, 2004 700+ words
...subject areas of Leishmaniasis, Leishmaniasis Vaccine, Vaccine Development, Immunology...This article was prepared by Vaccine Weekly editors from staff and other reports. Copyright 2004, Vaccine Weekly via NewsRx.com & NewsRx...
Source: HighBeam Research, Leishmaniasis vaccine protects susceptible mice from virulent...